Online inquiry

IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ291MR)

This product GTTS-WQ291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ652MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ15150MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ13276MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ14150MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ12685MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ2233MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ6312MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ1235MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW